Latest news with #Carvykti
Yahoo
21-07-2025
- Business
- Yahoo
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
An updated edition of the June 10, 2025, article. The global cancer treatment market is experiencing rapid growth, driven by rising cancer incidence, aging population and increasing demand for safer, more effective therapies. Per the American Cancer Society, in the United States alone, over 2 million new cancer cases and 618,000 related deaths are projected for 2025. Breakthroughs in immunotherapy, targeted treatments, and personalized cancer vaccines are reshaping the oncology landscape. These next-generation therapies offer greater precision and improved outcomes, supporting strong market expansion. Major pharma companies — including Novartis NVS, AstraZeneca AZN, Johnson & Johnson JNJ, Pfizer PFE, AbbVie ABBV, Bristol Myers Squibb and Eli Lilly LLY — are investing heavily in cutting-edge approaches like antibody-drug conjugates (ADCs) and immuno-oncology agents. Meanwhile, smaller biotechs are driving innovation, making them attractive acquisition targets for larger players seeking to enhance their oncology pipelines. As scientific progress accelerates, the oncology market is poised for robust, long-term growth — offering compelling opportunities for investors. These factors highlight the huge potential of cancer-focused companies. With our thematic screens, you can easily spot stocks tied to trends shaping the future of investing. If the cancer space appeals to you and you're looking to align your portfolio with this rising trend, now might be the time to consider stocks like J&J, Novartis and Allogene Therapeutics ALLO 3 Cancer Stocks in Focus J&J's Oncology segment comprises around 27% of its total revenues. Its oncology sales rose 22.3% on an operational basis in the second quarter of 2025 to $6.3 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant plus Lazcluze, contributed significantly to growth as they witnessed strong launches. On its second-quarter conference call, J&J stated that it expects its oncology sales to reach $50 billion by the end of the decade. J&J seems quite confident in the target, citing strong growth in its marketed cancer drugs and the potential of upcoming launches like TAR-200 in bladder cancer and the subcutaneous formulation of Rybrevant plus Lazcluze for advanced EGFR-mutated non-small cell lung cancer (NSCLC). TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. The subcutaneous formulation of Rybrevant plus Lazcluze has been recommended for approval in the EU while it is under review in the United States. J&J's oncology pipeline has gained strong momentum in the last year and a half, with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio. J&J has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Novartis has a diverse oncology portfolio, including targeted therapies and immunotherapies. The FDA's approval of Kisqali, its CDK4/6 inhibitor for the first-line treatment of postmenopausal women with HR+/HER2 advanced or metastatic breast cancer, significantly boosted the company's oncology portfolio, with the drug now being one of the top growth drivers for the company. In particular, Kisqali has shown robust uptake in the metastatic breast cancer setting. The recent approval of a broader label for Kisqali in the United States and the EU should further fuel its sales. Kisqali recorded sales of $1.1 billion in the second quarter of 2025, up 64% year over year. Other new oncology drugs like Pluvicto (PSMA-positive metastatic castration-resistant prostate cancer) and Scemblix (chronic myeloid leukemia) also put up a stellar performance, setting the momentum for the coming years as well. Novartis' oncology sales rose 20% in constant currency terms to $4.3 billion in the second quarter of 2025. In 2024, Novartis acquired Mariana Oncology and Germany-based MorphoSys AG, which strengthened its oncology pipeline. This Zacks Rank #2 company is also investing in research to develop treatments for both common and rare cancers, focusing on precision medicine strategies. Allogene Therapeutics is focused on developing allogeneic CAR T therapies for treating cancer, especially hematologic indications with high unmet needs. This Zacks Rank #2 company has multiple pipeline candidates in the clinical stage of development, including CAR T cell product candidates — cemacabtagene ansegedleucel (cema-cel or formerly ALLO-501A) and ALLO-316 for cancer indications. Lead candidate, cema-cel, is being developed as a frontline treatment for patients with large B-cell lymphoma (LBCL). In this regard, the company has initiated the pivotal phase II ALPHA3 study to evaluate cema-cel in patients with first-line LBCL. ALLO-316, the company's first CAR T candidate for solid tumors, is being evaluated in the TRAVERSE study in adults with advanced or metastatic renal cell carcinoma. Data from the study has shown that the therapy-induced early anti-tumor activity with deepening responses over time, especially in heavily pre-treated patients with high CD70 expression. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
05-07-2025
- Business
- Yahoo
Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds
Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy. Asad Haider, a Goldman Sachs analyst, remained optimistic about Johnson & Johnson (NYSE:JNJ) shares, rating it as a Buy on June 5. The analyst noted several factors that lead to the update. Pixabay/Public Domain Similar to its industry peers, the company demonstrates a proactive approach to navigating regulatory environments by participating in policy discussions with the administration. This could result in positive outcomes in areas such as 340B reform and PBM. Johnson & Johnson's innovation skills are further demonstrated by the company's pharmaceutical pipeline achievements, including the encouraging Carvykti data and the expected approval of TAR-200. The company's strategic move from Stelara to Tremfya and its investments in commercial fulfillment further highlight its commitment to preserving a dominant market position. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-07-2025
- Business
- Yahoo
Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds
Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy. Asad Haider, a Goldman Sachs analyst, remained optimistic about Johnson & Johnson (NYSE:JNJ) shares, rating it as a Buy on June 5. The analyst noted several factors that lead to the update. Pixabay/Public Domain Similar to its industry peers, the company demonstrates a proactive approach to navigating regulatory environments by participating in policy discussions with the administration. This could result in positive outcomes in areas such as 340B reform and PBM. Johnson & Johnson's innovation skills are further demonstrated by the company's pharmaceutical pipeline achievements, including the encouraging Carvykti data and the expected approval of TAR-200. The company's strategic move from Stelara to Tremfya and its investments in commercial fulfillment further highlight its commitment to preserving a dominant market position. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Medical News Today
02-07-2025
- Health
- Medical News Today
Carvykti interactions: Alcohol, medications, and other factors
Carvykti isn't known to interact with alcohol, other drugs, or supplements. However, the drug may interact with certain lab tests and vaccines. Talk with your doctor to avoid potentially harmful effects from Carvykti is prescribed for relapsed or refractory multiple myeloma in certain adults. An interaction occurs when one substance causes another substance to have a different effect than learning about possible Carvykti interactions, you can work with your doctor to ensure that Carvykti will be safe and effective for you.»Learn more about Carvykti, including details about its interactions with other drugs Carvykti is not known to interact with other medications. However, that doesn't mean interactions aren't possible. For example, other drugs may be approved in the future that may interact with you start treatment with Carvykti, tell your doctor and pharmacist about any prescription, over-the-counter, and other medications you take. By sharing this information with them, you may help prevent possible interactions. (To learn whether Carvykti interacts with supplements, herbs, or vitamins, see the 'Carvykti and other interactions' section.)If you have questions about drug interactions that may affect you, ask your doctor or and alcohol There are no known interactions between Carvykti and you have questions about drinking alcohol during Carvykti treatment, talk with your doctor or and other interactions Carvykti may have other interactions, such as with supplements, foods, vaccines, or lab are some potential interactions with Carvykti. Keep in mind that the following information does not include all possible Carvykti interactions with supplementsIt's possible for drugs to interact with supplements, such as vitamins and interactions with herbsThere are no specific reports of herbs interacting with Carvykti. However, that doesn't mean herbal interactions won't occur or be recognized in the future. Because of this, it's important to check with your doctor or pharmacist before taking any of these products during Carvykti interactions with vitamins There are no specific reports of vitamins interacting with Carvykti. However, that doesn't mean vitamin interactions won't occur or be recognized in the future. Because of this, you should talk with your doctor or pharmacist before taking any vitamin product with interactions with foodThere were no reports of food interactions with Carvykti. If you'd like to learn more about eating certain foods during treatment with Carvykti, talk with your interactions with vaccinesCarvykti may interact with live vaccines. A live vaccine contains live but weakened pieces of the virus or bacterium it's meant to defend against. When your immune system is healthy, live vaccines usually won't cause Carvykti works by weakening your immune system. If you get a live vaccine, your immune system may not be able to fight the virus or bacterium. This may cause you to become sick or develop symptoms of the illness the vaccine is meant to help prevent. Due to this risk, it's recommended that you avoid live vaccines for at least 6 weeks before, during, and after Carvykti treatment until your immune system has fully vaccines to avoid with Carvykti treatment include:measles, mumps, rubella (MMR)chickenpoxthe nasal spray form of the flu vaccine (FluMist)Before starting Carvykti, talk with your doctor or pharmacist about any vaccines you may interactions with lab testsCarvykti may interfere with the results of certain HIV tests, such as HIV RNA tests. Receiving Carvykti may cause a false-positive result on some HIV tests. This means the test could show that you have HIV even if you do of this, it's important to tell the person giving you the test that you're having Carvykti additional information, talk with your doctor or INTERACTION WITH CANNABIS OR CBDCannabis (often called marijuana) and cannabis products, such as cannabidiol (CBD), have not been specifically reported to interact with Carvykti. However, as with any drug or supplement, talk with your doctor before using cannabis in combination with Carvykti. The impact of cannabis may affect how well you stick to your Carvykti treatment Cannabis is illegal at a federal level but is legal in many states to varying and health-related interactionsCertain medical conditions and other factors may increase the risk of interactions with Carvykti. Before you start treatment with this drug, be sure to talk with your doctor about your health history. Carvykti may not be the right treatment option if you have certain medical conditions or other factors affecting your conditions or factors that might interact with Carvykti include:Kidney, liver, heart, or lung problems: Carvykti can cause a wide range of side effects, including kidney problems, elevated liver enzymes, heart problems, and breathing problems. If you already have kidney, liver, heart, or lung problems, you may be more likely to experience these side effects of Carvykti. Your doctor can discuss whether it's safe for you to start Carvykti or past nervous system problems: Carvykti has a boxed warning regarding the risk of neurologic toxicity (damage to your nervous system). A boxed warning is the most serious warning from the Food and Drug Administration (FDA). If you have a history of nervous system problems, including seizures, stroke, or memory issues, tell your doctor. You may have a higher risk of developing neurologic toxicity with Carvykti. See the 'Boxed warnings' section at the top of this article for more information. Current or past infection or inflammatory conditions: Carvykti can cause severe, life threatening, or fatal infection. Due to this risk, doctors typically will not start Carvykti treatment until your infection or inflammatory condition has reaction: If you've had an allergic reaction to Carvykti or any of its ingredients, your doctor will likely not prescribe Carvykti. Receiving the drug could cause another allergic reaction. You can ask them about other treatments that may be better choices for It's not known whether it's safe to receive Carvykti while breastfeeding. There isn't enough information to determine whether the drug passes into breast milk or what effects Carvykti may have on a child who is breastfed. If you're breastfeeding or planning to, talk with your doctor before starting Carvykti treatment. They can talk with you about treatment options and ways to feed a child other than There haven't been enough clinical trials to determine whether Carvykti is safe to receive while pregnant. If you're pregnant or planning to become pregnant, tell your doctor before starting Carvykti treatment. They can advise you on the right treatment plan for interactions You can take certain steps to help prevent interactions with Carvykti. Your doctor and pharmacist are key resources, so reaching out to them before starting treatment is a helpful first step. For example, it's important that you plan to do the following:Let them know if you drink alcohol or use them about any other medications you take, as well as any supplements, herbs, and vitamins, especially before receiving vaccines. Create a medication list, which your doctor and pharmacist can help you fill also important to read the Carvykti label and other paperwork that may come with the drug. The label may have colored stickers that mention an interaction. The paperwork, sometimes called the medication guide or patient package insert, may contain details about Carvykti doesn't come with paperwork, you can ask your doctor to print a copy. If you need help reading or understanding this information, ask your doctor or Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
Time of India
28-06-2025
- Health
- Time of India
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies
Bengaluru: The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a safety program to protect patients from risky drugs, for currently approved CAR-T cell immunotherapies. REMS is required by the FDA to ensure a drug's benefits outweigh its risks by managing serious safety concerns. The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed warnings for cytokine release syndrome and neurological toxicities, and medication guides. The cancer therapies include Bristol-Myers Squibb's Breyanzi and its partnered therapy Abecma with 2seventy bio , Johnson & Johnson's unit Janssen and Legend Biotech's Carvykti, Novartis AG's Kymriah, and Gilead Sciences' unit Kite's Tecartus and Yescarta. Bristol-Myers Squibb and Gilead Sciences did not immediately respond to Reuters' requests for comment. These are gene therapies that are currently approved to treat blood cancers, such as multiple myeloma and certain types of leukemia and lymphoma, the health regulator said. CAR-T treatment generally involves extracting disease-fighting white blood cells known as T-cells from a patient, re-engineering them to attack cancer and infusing them back into the body. In January 2024, the FDA asked several drugmakers to add a serious warning on the label of their cancer therapies that use CAR-T technology after reports of T-cell malignancies and adverse events identified since approval. The FDA earlier said the risk of T-cell malignancies including leukemia and lymphoma applies to all therapies in the class and can lead to hospitalization and death.
